IMVT Immunovant, Inc.

NASDAQ
$31.77

Immunovant, Inc. (IMVT) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $0.64 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.7% since its last earnings release on November 9, 2026.

Immunovant Beat Consensus Estimates
Monday, November 9, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Dec 2026
Feb 8
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($0.64)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $34.66

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Immunovant, Inc.

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.